Immuneering (NASDAQ: IMRX) net income
Immuneering reported a net loss of $56.0m for fiscal 2025; in fiscal 2024 it reported a net loss of $61.0m. Earnings per share were −$1.27.
Immuneering's best year of the last 6 was fiscal 2020. It reported a loss in 6 of those 6 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −$56.0m | — | — | −$1.27 |
| 2024 | −$61.0m | — | — | −$2.04 |
| 2023 | −$53.5m | — | — | −$1.88 |
| 2022 | −$50.5m | — | −15,937.3% | −$1.91 |
| 2021 | −$33.5m | — | −1,612.3% | −$2.46 |
| 2020 | −$17.0m | — | −737.2% | −$3.44 |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Immuneering net income compared with its sector
By net income for its latest fiscal year, Immuneering ranks 268th of the 501 US health care companies with a page on Celsmar.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 266th | Connect Biopharma | −$55.5m | −86,687.5% |
| 267th | Azenta | −$55.8m | −9.4% |
| 268th | Immuneering | −$56.0m | — |
| 269th | Relmada Therapeutics | −$57.4m | — |
| 270th | Protara Therapeutics | −$57.4m | — |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Immuneering
- How much did Immuneering earn in fiscal 2025?
- Immuneering reported a net loss of $56.0m for fiscal 2025. In fiscal 2024 it reported a net loss of $61.0m.
- What are the earnings per share of Immuneering?
- They were −$1.27 in fiscal 2025, compared with −$2.04 in fiscal 2024.
- Where does Immuneering rank in its sector by net income?
- It ranks 268th of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Immuneering come from?
- From the annual report (Form 10-K) that Immuneering files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Immuneering files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020. More on Immuneering: the Immuneering page · annual accounts · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.